Cell and gene therapies are no longer a niche category. With more approvals coming through, payers pushing back harder, and health systems struggling to keep up operationally, CGT commercialisation has entered a very different phase. For investors, manufacturers, and global launch teams, the question is... Continue reading
Return to previous page